Search

Viking Therapeutics Inc

Fechado

SetorSaúde

29.92 -4.65

Visão Geral

Variação de preço das ações

24h

Atual

Mín

29.67

Máximo

31.52

Indicadores-chave

By Trading Economics

Rendimento

30M

-128M

EPS

-1.1

Funcionários

65

EBITDA

30M

-128M

Recomendações

By TipRanks

Recomendações

Compra Forte

Previsão para 12 meses

+185.71% upside

Dividendos

By Acuity

Próximos Ganhos

21 de out. de 2026

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

-371M

3.7B

Abertura anterior

34.57

Fecho anterior

29.92

Sentimento de Notícias

By Acuity

50%

50%

129 / 339 Ranking em Healthcare

Viking Therapeutics Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

15 de set. de 2026, 23:02 UTC

Viking Therapeutics Inc shares are higher during after-market hours, reflecting broader market trends despite recent economic indicators suggesting a slowdown in manufacturing.

14 de set. de 2026, 19:36 UTC

Viking Therapeutics Inc shares are lower, continuing a trend of declines amid broader market weakness and rising crude oil prices affecting sentiment.

11 de set. de 2026, 23:06 UTC

Viking Therapeutics Inc. shares are higher in after-market trading, despite routine fluctuations, and remain below their 20-day moving average.

10 de set. de 2026, 20:07 UTC

Correlated Moves
Social Media

Viking Therapeutics Inc shares are lower, influenced by a declining broader market and volatility in the biotech sector amid rising Treasury yields and inflation concerns.

9 de set. de 2026, 23:11 UTC

Viking Therapeutics Inc shares are higher in after-market trading, recovering from earlier lows despite being below the 20-day moving average. No specific news was identified.

2 de set. de 2026, 19:46 UTC

Viking Therapeutics Inc shares are lower today, pulling back from earlier session highs amid broader market concerns over rising U.S. Treasury yields.

31 de ago. de 2026, 19:36 UTC

Viking Therapeutics shares are higher today, despite earlier pressure, amid broader market dynamics influenced by rising interest rate expectations following comments from the Fed.

29 de ago. de 2026, 00:01 UTC

Viking Therapeutics Inc shares rose in after-market trading, reflecting a notable increase since Friday's close, despite no specific news driving the movement.

28 de ago. de 2026, 23:36 UTC

Viking Therapeutics Inc. shares are higher in after-market trading, gaining since Friday's close, despite fluctuations and remaining below the 20-day moving average.

27 de ago. de 2026, 23:02 UTC

Viking Therapeutics Inc shares are higher in after-market hours following notable volatility during the session, despite no specific news to explain the movement.

26 de ago. de 2026, 19:16 UTC

Viking Therapeutics Inc shares are higher today, though no specific news was identified to explain the price movement. The stock remains above its 20-day moving average.

25 de ago. de 2026, 23:16 UTC

Viking Therapeutics shares are lower in after-market hours amid broader market volatility, with falling oil prices and geopolitical developments affecting investor sentiment.

24 de ago. de 2026, 19:56 UTC

Social Media

Viking Therapeutics Inc shares are lower today, continuing a decline since Friday. Social media discussions highlight anticipation for upcoming data before Labor Day.

20 de ago. de 2026, 20:06 UTC

Macro Event
Social Media

Viking Therapeutics Inc shares are lower, impacted by labor market data and heightened volatility, despite social media discussions suggesting potential recovery from a clinical trial.

19 de ago. de 2026, 23:16 UTC

Viking Therapeutics Inc shares are higher in after-market hours, reflecting a gain since Wednesday's close and remaining above the 20-day moving average.

18 de ago. de 2026, 19:16 UTC

Viking Therapeutics Inc shares are lower today, with no specific news driving the decline amid rising U.S. Treasury yields affecting the biotechnology sector.

17 de ago. de 2026, 23:06 UTC

Viking Therapeutics Inc shares are higher in after-market trading, reflecting unusual strength. No specific company news was identified to explain the price movement.

14 de ago. de 2026, 23:06 UTC

Viking Therapeutics Inc shares are lower in after-market hours, trading at the lower end of their one-month range and below the 20-day moving average.

13 de ago. de 2026, 23:16 UTC

Viking Therapeutics Inc shares are lower in after-market trading, with no specific news identified to explain the decline. The stock is near its one-month low.

12 de ago. de 2026, 23:26 UTC

Viking Therapeutics Inc is trading lower in after-market hours, reflecting notable weakness with no specific news identified to explain the decline.

7 de ago. de 2026, 19:36 UTC

Social Media

Viking Therapeutics is rising amid broader market gains and anticipation of VK2809 trial results, with analysts noting potential for improved market position.

6 de ago. de 2026, 23:16 UTC

Social Media

Viking Therapeutics Inc gains in after-market hours amid discussions on pharmacokinetic modeling and anticipated VKTX maintenance readout results.

5 de ago. de 2026, 22:51 UTC

Viking Therapeutics Inc. shares are lower in after-market hours, continuing a decline from Wednesday's close amid unusual volatility and trading below the 20-day moving average.

4 de ago. de 2026, 23:02 UTC

Social Media

Viking Therapeutics Inc shares are lower in after-market hours amid routine trading. The stock remains below its 20-day moving average.

3 de ago. de 2026, 23:06 UTC

Viking Therapeutics shares are higher in after-market trading, reflecting positive sentiment from stronger-than-expected manufacturing PMI data indicating sector growth.

31 de jul. de 2026, 23:51 UTC

Viking Therapeutics Inc is higher in after-market trading, recovering from earlier session lows after four consecutive declines. The stock remains below its 20-day moving average.

30 de jul. de 2026, 23:56 UTC

News

Viking Therapeutics Inc. shows a modest gain in after-market hours amid a wave of biopharmaceutical mergers, including Vertex's $10 billion acquisition of Crinetics.

29 de jul. de 2026, 23:21 UTC

Social Media
News

Viking Therapeutics reported a Q2 loss of $1.10 per share, better than expected. The company highlighted progress in its obesity treatment pipeline.

28 de jul. de 2026, 23:11 UTC

News

Viking Therapeutics shares are lower in after-market hours amid ongoing challenges and a significant decline over the past two years. Analysts maintain a bullish outlook.

27 de jul. de 2026, 23:56 UTC

Viking Therapeutics Inc shares are lower in after-market hours, reflecting a lack of specific news and remaining below the 20-day moving average.

Comparação entre Pares

Variação de preço

Viking Therapeutics Inc Previsão

Preço-alvo

By TipRanks

185.71% parte superior

Previsão para 12 meses

Média 90.083 USD  185.71%

Máximo 114 USD

Mínimo 65 USD

Com base em 14 analistas de Wall Street que oferecem metas de preço de 12 meses para Viking Therapeutics Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

14 ratings

14

Comprar

0

Manter

0

Vender

Sentimento

By Acuity

129 / 339 Ranking em Saúde

Sentimento de Notícias

Neutral

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Abaixo da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Viking Therapeutics Inc

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.
help-icon Live chat